Close

Tag: Coronavirus information (COVID-19)

Pharma Majors Collaborate for Clinical Trial of Investigational Oral Anti-Viral Drug Molnupiravir for COVID-19

Cipla Limited, Dr. Reddy’s Laboratories Ltd., Emcure Pharmaceuticals Limited, Sun Pharmaceutical Industries Limited, and Torrent Pharmaceuticals Limited, announced that the five companies will collaborate...

Sanofi launches dedicated vaccines mRNA Center of Excellence

Sanofi will invest approximately €400 million annually in a first-of-its kind vaccines mRNA Center of Excellence. The Center will work to accelerate the development...

Clover Announces Advance Purchase Agreement with Gavi for Over 400 Million Doses of Clover’s COVID-19 Vaccine for the COVAX Facility

Clover Biopharmaceuticals (Clover), a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates to address the world's most life-threatening diseases and public...

Mixed Oxford/Pfizer vaccine schedules generate robust immune response against COVID-19, finds Oxford-led study

Alternating doses of the Oxford-AstraZeneca and Pfizer-BioNTech vaccines generate robust immune responses against COVID-19, according to researchers running the University of Oxford-led Com-COV study. In...

Moderna Announces Emergency Use Authorization for its COVID-19 Vaccine Granted by Government of India

Moderna, Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announced that the government of India has issued a registration certificate and...

RedHill Biopharmas opaganib shows activity against Covid-19 variants

RedHill Biopharma has reported initial findings from a preclinical study, which revealed that its drug candidate, opaganib (Yeliva, ABC294640), could block Covid-19 variants of...

CluePoints Launch Post-COVID Trial Assurance Solution

CluePoints, the premier provider of Risk-Based Quality Management Solutions for clinical trials, has launched a new Post-COVID Trial Assurance Solution as part of its mission...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from up to 5 devices at once

Must read